Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that ...

Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus ...

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...

Herantis Pharma has dosed the first patients in the final cohort of its phase 1b clinical trial assessing HER-096, a ...

AQILION AB (publ) today announces that the US Food and Drug Administration (FDA) has approved Aqilion's IND (investigational new drug) application for the drug candidate AQ280. The first study in the ...

Kaerus Bioscience has received orphan drug and rare paediatric drug designations from the FDA for KER-0193, its lead ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

UK-based Kaerus Bioscience, a biopharma created by European investment firm Medicxi for the development of therapeutics for ...

Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost ...

ATH-1105 is the Company's novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to ...

BioCardia, Inc. ( NASDAQ: BCDA) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Joe Pantginis - H.C. Wainwright Laura ...